about
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targetsChronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.NKX3.1 as a marker of prostatic origin in metastatic tumors.Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial.Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer.DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.A case of prostatic adenocarcinoma with aberrant p63 expression: presentation with detailed immunohistochemical study and FISH analysis.PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusionLangerhans' cell histiocytosis mimicking metastatic carcinoma of the lung.Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats.Benign mixed epithelial and stromal tumor of the kidney.High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate CancerGenomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair DeficiencyCan telomere alterations predict biochemical recurrence in prostate adenocarcinoma? A preliminary studyEffects of Ginkgo biloba extract on spinal cord ischemia-reperfusion injury in ratsScoring Idiopathic Granulomatous Mastitis: An Effective System for Predicting Recurrence?More than Ophelia syndrome: Multiple paraneoplastic syndromes in pediatric Hodgkin lymphomaOlaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialProstate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerGenomics of lethal prostate cancer at diagnosis and castration resistanceComparative Proteome Analysis of Breast Cancer Tissues Highlights the Importance of Glycerol-3-phosphate Dehydrogenase 1 and Monoacylglycerol Lipase in Breast Cancer Metabolism
P50
Q24629083-9EF52DF8-0E42-4225-8F81-8892FF1F8957Q33575062-66F60418-1367-42AA-8363-1FAE24D2B6BCQ34123290-FC72B7D7-6033-4717-9D2F-3EFBEF17AF14Q35815985-5F37996F-4575-4E2D-AEF9-38090EF39849Q35956281-23467885-42BB-4283-A390-914455E59E74Q36469889-B9B03A56-5F0A-49E8-A547-8B21B2A88150Q36655683-07784FEC-9CBD-4EA9-9357-10DEF99E6D3FQ39328341-27D07E19-1FF0-486C-9E5E-71E037F49FFEQ39923092-CF98A260-4991-4E93-83ED-F0FAEADA5F5EQ39946539-6550337B-0B65-43AC-9F23-75FB49DA6CC1Q41912121-5B1D7BAA-C342-4519-ADF9-F477C1D9EC64Q42119481-2323253E-4D8E-4575-9A4D-C9E15581E0CFQ46134088-6FD88B37-3D35-46FD-AB9F-D0697328FAA8Q46442470-21474582-9C07-4350-A63F-03C5DE018DAEQ51801727-B18436B4-1624-46C2-A1B8-7AAB67D1A469Q53176736-8F77B2D3-CB76-48D3-ADB9-978B064B1162Q57180413-B4E968E0-5C45-403F-B1A2-8351FC55EE50Q57814257-7179D4FA-D949-4480-8F6B-07044D01AAF9Q84624506-326EA39A-1F31-4951-91D1-0A2BAC58D329Q87342836-C1B11D8D-972F-4391-86DE-CC613D40B292Q88723006-9DD7CB76-D658-42B7-BF2F-D28EF50E771CQ90323650-2A49CF3E-D6F5-4B72-9DEB-EDF0BD2DA897Q91733148-788B5C2F-44BB-4C31-A042-1CB245B6F068Q92182846-25CA2519-50FE-4824-B31B-9F4F440E1F5CQ92234351-57C75F01-61D0-4A30-BFE9-0A3A0873DC35Q92994127-2C6D4319-39BF-49F4-8AFE-DCD0FB32C5E9
P50
description
investigador
@es
researcher
@en
name
Bora Gurel
@en
Bora Gurel
@nl
type
label
Bora Gurel
@en
Bora Gurel
@nl
prefLabel
Bora Gurel
@en
Bora Gurel
@nl
P31
P496
0000-0002-5018-8078